ArticleVirchows Archiv : an international journal of pathology2026
Thoracic inflammatory myofibroblastic tumors: A decade-long retrospective study integrating clinicopathological and molecular features from a tertiary care centre.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Inflammatory myofibroblastic tumors (IMT) are mesenchymal neoplasms of intermediate malignant potential, characterized by recurrent gene fusions in potentially targetable receptor tyrosine kinases. Primary thoracic IMTs are rare, and their molecular landscape remains incompletely characterized. A ten-year retrospective (2014-2024) clinicopathological analysis of primary thoracic IMTs was done. Histomorphological evaluation and molecular characterization by a graded approach incorporating immunohistochemistry, fluorescence-in-situ hybridization, multiplex reverse-transcription polymerase chain reaction, and next-generation targeted panel sequencing were performed for the common implicated driver fusions. Thirty IMTs involving the lung (n=17), tracheobronchial tree (n=12), and pleura (n=1) were identified. Median age at diagnosis was 18 years (range: 2 to 51 years), including 14 paediatric and 16 adult patients. Male: female ratio was 2.2:1 and 1.3:1, in adults and children, respectively. Majority (22/30, 73.3%) showed cellular spindle-cell pattern with lymphoplasmacytic inflammation. None showed significant atypia, necrosis, or mitotic activity. Molecular characterisation achieved in 22/30 cases revealed 73.3% (16/22) ALK-IMTs, 23% (5/22) ROS1-IMTs, and a single NTRK3-IMT. No statistically significant differences were seen among molecular subgroups, although ALK-IMTs were diagnosed at a higher median age (24.5 years) as compared to ROS1-IMTs (15 years). On follow-up (median follow up period: 24 months), local recurrence was observed in 23% (3/13) patients, all harbouring ALK-IMTs, one of whom was successfully treated with ALK inhibitor therapy; no disease-related deaths were recorded. Primary thoracic IMT affects children and young adults. Majority are driven by ALK gene rearrangements, followed by ROS1 alterations, underscoring role of molecular profiling in potential therapeutic stratification.
Indexed as
Identifiers
42067665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.